TherapeuticsMD Inc. Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%

Reuters

05-14

<a href="https://laohu8.com/S/TXMD">TherapeuticsMD Inc.</a> Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%

TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $(0.06) per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $(0.07) per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513022104) on May 13, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535848100"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535848100\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535848100?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535848100","market":"nz","top_or_hot":-1,"title":"TherapeuticsMD Inc. Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TXMD\">TherapeuticsMD Inc.</a> Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $(0.06) per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $(0.07) per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513022104) on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TherapeuticsMD Inc. Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTherapeuticsMD Inc. Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-14 04:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TXMD\">TherapeuticsMD Inc.</a> Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $(0.06) per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $(0.07) per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513022104) on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXMD","symbol_name":"TherapeuticsMD Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL17j2BT:1","article_id":"2535848100","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535848100","pubTimestamp":1747166785,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TherapeuticsMD, Inc.  reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $ per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $ per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 mi","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TXMD":"TherapeuticsMD Inc."},"translate_title":"TherapeuticsMD Inc.报告2025年第一季度：净亏损收窄至63.6万美元，许可收入增长25.8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXMD":0.9},"content_text":"TherapeuticsMD Inc. Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%\n    \n\n        TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $(0.06) per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $(0.07) per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 million.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513022104) on May 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}